SRY-box transcription factor 2 (Sox2) peptide antigen (Sox2 peptide)

SRY-box transcription factor 2 (Sox2) is a critical transcription factor involved in the maintenance of self-renewal and pluripotency in embryonic stem cells and is frequently overexpressed in various malignancies, including lung, breast, and brain cancers. In the context of oncology, Sox2-derived peptide antigens are short amino acid sequences from the Sox2 protein that are processed and presented by Major Histocompatibility Complex (MHC) molecules on the cell surface. These peptides serve as targets for the immune system, specifically for CD8+ cytotoxic T cells and CD4+ helper T cells, making them valuable candidates for cancer immunotherapy. Therapeutic strategies targeting these antigens include peptide-based vaccines and T-cell receptor (TCR) engineered T-cell therapies designed to elicit a robust anti-tumor immune response. Because Sox2 is often associated with 'cancer stemness' and resistance to conventional therapies, targeting its derived peptides offers a way to eliminate the most resilient cell populations within a tumor. However, clinical application requires careful patient selection based on HLA type and Sox2 expression levels to ensure efficacy and minimize potential autoimmune reactions against normal progenitor cells.

Other names

Sox2-derived peptidesSox2 epitopesSRY-box 2 antigenTranscription factor SOX-2 peptides

Induction of antigen-specific cytotoxic T lymphocytes (CTLs) and Th1-type helper T cells that recognize Sox2-derived epitopes presented by MHC molecules on the surface of tumor cells, leading to targeted cell lysis.